{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:07:13Z","timestamp":1781626033274,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Given the chronic inflammatory nature of juvenile idiopathic arthritis (JIA), disease complications may occur including chronic joint damage, ocular complications, and growth restrictions. Few studies have provided a comprehensive assessment of disease complication rates in a contemporary population of patients with JIA. The primary objective of this study was to provide a comprehensive report of disease complications in our JIA population. Secondary objectives included characterizing patients who developed complications and identifying associated risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective cohort study. A standardized list of JIA disease complications was created by consensus among rheumatologists and included in the electronic medical record. A total of 432 patients diagnosed with JIA for more than one year were evaluated at our rheumatology clinic between January 2023 and February 2024 and were assessed for the development of disease complications. Univariate analysis was used to test for associations between the presence of complications and potential risk factors such as sex, age of disease onset, diagnosis duration, serology positivity, and treatment history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 432 patients, 146 (33.8%) were identified to have at least one disease complication. Joint complications occurred in 73 patients (16.9%), and uveitis was identified in 57 patients (13.2%), with 14 (25%) of those experiencing secondary ocular complications. Growth failure was observed in 4% of patients, with short stature resulting in 1%. Younger age at disease onset and longer time to initiation of biologic therapy were associated with an increased risk of developing complications. Additionally, delayed initial rheumatology evaluation and delayed initiation of biologic therapy were both associated with a progressively increasing risk of joint complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite therapeutic advances in the treatment of JIA, a substantial proportion of patients continue to develop disease complications. Approximately one-third of patients in our cohort experienced at least one disease complication. Delayed initiation of biologic therapy was associated with higher complication rates, highlighting the importance of early therapeutic intervention to reduce the burden of disease complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-025-01180-6","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:52:57Z","timestamp":1766393577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comprehensive report of disease complications of juvenile idiopathic arthritis using a prospective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Jacob","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleo","family":"Ede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shishov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Wershba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"1180_CR1","doi-asserted-by":"crossref","unstructured":"Karen N. O. Overview of juvenile idiopathic Arthritis. The open orthopaedics journal. 2020. pp. 101\u20139.","DOI":"10.2174\/1874325002014010101"},{"issue":"2","key":"1180_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"2","key":"1180_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4274\/balkanmedj.2017.0111","volume":"34","author":"K Barut","year":"2017","unstructured":"Barut K, Adrovic A, \u015eahin S, Kasap\u00e7opur \u00d6. Juvenile idiopathic arthritis. Balkan Med J. 2017;34(2):90\u2013101. https:\/\/doi.org\/10.4274\/balkanmedj.2017.0111.","journal-title":"Balkan Med J"},{"issue":"8","key":"1180_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/children8080646","volume":"8","author":"E Carlsson","year":"2021","unstructured":"Carlsson E, Beresford MW, Ramanan AV, Dick AD, Hedrich CM. Juvenile idiopathic arthritis associated uveitis. Child (Basel). 2021;8(8):646. https:\/\/doi.org\/10.3390\/children8080646. Published 2021 Jul 27.","journal-title":"Child (Basel)"},{"issue":"3","key":"1180_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/09273948.2013.791701","volume":"21","author":"A Heiligenhaus","year":"2013","unstructured":"Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm. 2013;21(3):180\u201391. https:\/\/doi.org\/10.3109\/09273948.2013.791701.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"1180_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/09273948.2015.1115878","volume":"24","author":"K Abu Samra","year":"2016","unstructured":"Abu Samra K, Maghsoudlou A, Roohipoor R, Valdes-Navarro M, Lee S, Foster CS. Current treatment modalities of JIA-associated uveitis and its complications: literature review. Ocul Immunol Inflamm. 2016;24(4):431\u20139. https:\/\/doi.org\/10.3109\/09273948.2015.1115878.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"1180_CR7","first-page":"929","volume":"36","author":"A Marino","year":"2018","unstructured":"Marino A, Stagi S, Simonini G, et al. Growth and body mass index in a cohort of patients with juvenile idiopathic arthritis: effects of second line treatments. Clin Exp Rheumatol. 2018;36(5):929\u201333.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"1180_CR8","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160\u20139. https:\/\/doi.org\/10.1002\/art.38802.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1180_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12098-017-2293-5","volume":"84","author":"M Dewoolkar","year":"2017","unstructured":"Dewoolkar M, Cimaz R, Chickermane PR, Khubchandani RP, Course. Outcome and complications in children with systemic onset juvenile idiopathic arthritis. Indian J Pediatr. 2017;84(4):294\u20138. https:\/\/doi.org\/10.1007\/s12098-017-2293-5. Epub 2017 Feb 23. PMID: 28229369.","journal-title":"Indian J Pediatr"},{"issue":"4","key":"1180_CR10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/1756-185X.12886","volume":"21","author":"NVB Menon","year":"2018","unstructured":"Menon NVB, Peethambaran G, Puthiyapurayil AT, Nambudakath C, Arakkal R. Clinical profile and juvenile arthritis damage index in children with juvenile idiopathic arthritis: A study from a tertiary care center in South India. Int J Rheum Dis. 2018;21(4):871\u20139. https:\/\/doi.org\/10.1111\/1756-185X.12886. Epub 2016 Jun 16. PMID: 27309679.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"1180_CR11","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1097\/PRS.0b013e3181f44abc","volume":"126","author":"JW Song","year":"2010","unstructured":"Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010;126(6):2234\u201342. https:\/\/doi.org\/10.1097\/PRS.0b013e3181f44abc. PMID: 20697313; PMCID: PMC2998589.","journal-title":"Plast Reconstr Surg"},{"key":"1180_CR12","unstructured":"World Health Organization. WHO Multicentre Growth Reference Study Group: WHO child growth standards: length\/height-for-age: Methods and development. Geneva: WHO 2007. (2006)."},{"issue":"246","key":"1180_CR13","first-page":"1","volume":"11","author":"RJ Kuczmarski","year":"2002","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the united states: methods and development. Vital Health Stat. 2002;11(246):1\u2013190.","journal-title":"Vital Health Stat"},{"issue":"2","key":"1180_CR14","doi-asserted-by":"publisher","first-page":"105501","DOI":"10.1016\/j.jbspin.2022.105501","volume":"90","author":"A Combier","year":"2023","unstructured":"Combier A, Frantz C, Wipff J, et al. Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood. Joint Bone Spine. 2023;90(2):105501. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105501.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"1180_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10067-015-2971-5","volume":"35","author":"M Sp\u00e2rchez","year":"2016","unstructured":"Sp\u00e2rchez M, Miu N, Bolba C, Iancu M, Sp\u00e2rchez Z, Rednic S. Evaluation of anti-cyclic citrullinated peptide antibodies May be beneficial in RF-negative juvenile idiopathic arthritis patients. Clin Rheumatol. 2016;35(3):601\u20137. https:\/\/doi.org\/10.1007\/s10067-015-2971-5.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1180_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jbspin.2012.03.008","volume":"80","author":"A Omar","year":"2013","unstructured":"Omar A, Abo-Elyoun I, Hussein H, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine. 2013;80(1):38\u201343. https:\/\/doi.org\/10.1016\/j.jbspin.2012.03.008.","journal-title":"Joint Bone Spine"},{"issue":"5","key":"1180_CR17","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3899\/jrheum.110879","volume":"39","author":"J Lipinska","year":"2012","unstructured":"Lipinska J, Br\u00f3zik H, Stanczyk J, Smolewska E. Anticitrullinated protein antibodies and radiological progression in juvenile idiopathic arthritis. J Rheumatol. 2012;39(5):1078\u201387. https:\/\/doi.org\/10.3899\/jrheum.110879.","journal-title":"J Rheumatol"},{"issue":"3","key":"1180_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00417-005-0087-3","volume":"244","author":"PE Carvounis","year":"2006","unstructured":"Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):281\u201390. https:\/\/doi.org\/10.1007\/s00417-005-0087-3.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1180_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ophtha.2020.08.024","volume":"128","author":"V Rypdal","year":"2021","unstructured":"Rypdal V, Glerup M, Songstad NT, et al. Uveitis in juvenile idiopathic arthritis: 18-Year outcome in the Population-based nordic cohort study. Ophthalmology. 2021;128(4):598\u2013608. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.024.","journal-title":"Ophthalmology"},{"issue":"2","key":"1180_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/art.22381","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56(2):647\u201357. https:\/\/doi.org\/10.1002\/art.22381.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1180_CR21","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3899\/jrheum.130302","volume":"40","author":"ST Angeles-Han","year":"2013","unstructured":"Angeles-Han ST, Pelajo CF, Vogler LB, et al. Risk markers of juvenile idiopathic arthritis-associated uveitis in the childhood arthritis and rheumatology research alliance (CARRA) registry. J Rheumatol. 2013;40(12):2088\u201396. https:\/\/doi.org\/10.3899\/jrheum.130302.","journal-title":"J Rheumatol"},{"issue":"1","key":"1180_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12969-021-00521-5","volume":"19","author":"DM D\u2019Angelo","year":"2021","unstructured":"D\u2019Angelo DM, Di Donato G, Breda L, Chiarelli F. Growth and puberty in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021;19(1):28. https:\/\/doi.org\/10.1186\/s12969-021-00521-5. Published 2021 Mar 12.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1180_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semarthrit.2017.11.002","volume":"48","author":"F McErlane","year":"2018","unstructured":"McErlane F, Carrasco R, Kearsley-Fleet L, Baildam EM, Wedderburn LR, Foster HE, Ioannou Y, Chieng SEA, Davidson JE, Thomson W, Hyrich KL. Growth patterns in early juvenile idiopathic arthritis: results from the childhood arthritis prospective study (CAPS). Semin Arthritis Rheum. 2018;48(1):53\u201360. Epub 2017 Nov 7. PMID: 29217290; PMCID: PMC6089842.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 1","key":"1180_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000229759","volume":"72","author":"K Minden","year":"2009","unstructured":"Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72(Suppl 1):20\u20135. https:\/\/doi.org\/10.1159\/000229759.","journal-title":"Horm Res"},{"issue":"5","key":"1180_CR25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jpeds.2011.04.012","volume":"159","author":"S Padeh","year":"2011","unstructured":"Padeh S, Pinhas-Hamiel O, Zimmermann-Sloutskis D, Berkun Y. Children with oligoarticular juvenile idiopathic arthritis are at considerable risk for growth retardation. J Pediatr. 2011;159(5):832\u2013e8378372. https:\/\/doi.org\/10.1016\/j.jpeds.2011.04.012.","journal-title":"J Pediatr"},{"issue":"6","key":"1180_CR26","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3899\/jrheum.141261","volume":"42","author":"F Minoia","year":"2015","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Rheumatol. 2015;42(6):994\u20131001. https:\/\/doi.org\/10.3899\/jrheum.141261.","journal-title":"J Rheumatol"},{"key":"1180_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. https:\/\/doi.org\/10.3389\/fimmu.2019.00119. PMID: 30774631; PMCID: PMC6367262.","journal-title":"Front Immunol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01180-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01180-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01180-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:33:33Z","timestamp":1781624013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-025-01180-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01180-6","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval to conduct this study was obtained by Phoenix Children\u2019s Institutional Review Board (IRB-24-174).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}